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Septicemia due to gram-negative bacteria is a serious problem for all debilitated 
patients,' and especially those with severe burns. Pseudomonas aeruginosa 
emerged as the most common organism found in burned patients who died from 
septicemia.2 This presentation reviews the laboratory work and clinical trials with 
both pseudomonas vaccine and hyperimmune plasma in the treatment of the 
severely burned patient and brings up to date the results previously r e p ~ r t e d . ~  
It is necessary to define the severe burn, since patients with small and moderate 
burns are usually not troubled by gram-negative septicemia. The severe burn in 
this report is defined as one involving a minimum of twenty percent full-thickness 
skin loss (third degree) or forty percent total body burn (second and third 
degree). 
A series of rabbit experiments designed to determine the antibody response 
to active immunization with the injection of a pseudomonas vaccine were com- 
pleted five years ago.4 An antibody response was obtained in four weeks, and the 
six-pound rabbits were then found to have eighty percent protection against 
i.v. injection of three billion live organisms, compared with a control group 
which did not receive the vaccine. A second set of rabbit experiments was con- 
ducted to determine the value of hyperimmune plasma for passive immunity. 
Again, a satisfactory protection was obtained by giving the hyperimmune plasma 
before and after the i.v. challenge of the live organisms. The vaccine was pre- 
pared for normal human volunteers. When tested, it was found that a longer time 
was required to develop a titer in the human than in the rabbit, but a good anti- 
body level could be achieved. There were no adverse reactions to the vaccine in 
the human volunteers and a hyperimmune plasma bank was established. The 
volunteers are now maintained at a high titer by interval vaccinations and their 
plasma is collected, frozen and stored. A daily program was started in which all 
adults with severe burns received 250 ml of the hyperimmune plasma while the 
children were given 125 ml. 
From July, 1959, to July 1966, 126 patients with burns greater than twenty 
percent being full-thickness, or wounds involving forty percent of the total body 
surface, were admitted to the University of Michigan Burn Unit. Patients who 
died in less than six days of causes other than infection are not included. All 
deaths after six days are included. TABLE 1 shows three different groups of 
patients during the six-year-period. It is understood that this is not an ideal 
method of comparing patients, but it does represent a trend in results, inasmuch 
as the same pattern of therapy is carried out today that was instituted in our 
Burn Unit six years ago. The use of hyperimmune plasma is a major change in 
infection control, while antibiotic therapy and dressing-change technique have 
not changed. 
The first group consisting of 41 patients, were treated prior to the use of the 
vaccine. The second group, of 24 patients, received the vaccine alone and not 
the hyperimmune plasma. The third group, of 61 patients, received the hyper- 
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TABLE 1 
PSEUOOMONAS VACCINE AND HYPERIMMUNE PLASMA IN BURN PATIENT TREATMENT* 
Vaccinated + 
Not Vaccinated Hyperimmune 
Vaccinated Only Plasma 
1. 11. 111. 
1959-62 1962-63 1963-1/66 
No. of Patients 41 24 61 
Av. Age (Yrs.) 26 24 24 
Av. % Total burns 5 1  40 44 
Av. % Full-thickness burns 38 31 30 
Deaths 
No. of deaths 19 9 1 1  
% Mortality 44 38  18 
Av. age (Yrs.) 34 26 43 
Av. % Full-thickness burns 46 40 52 
Septicemias 
Total No. 29 18 16 
% Septicemias (all patients) 71 75 26 
No. Septicemia deaths 17 9 6 
% Septicemia deaths of all deaths 88 100 55 
No. Pseudomonas septicemias 21 7 3 
5% Pseudomonas septicemias (all patients) 5 1  29 5 
% Pseudornonas septicemias of all septiccmias 72 39 19 
No. Pseudomonas deaths 13 6 2 
% Pseudomonas deaths, all patients 32 25 3 
* Summary of 126 cases with burns greater than 20% full-thickness or 40% total body 
surface, excluding deaths within six days of burn. 
immune plasma daily, as well as the weekly injection of the vaccine to help 
stimulate their own antibodies. The average age, percent total burn and percent 
full-thickness burn is given for each of the three groups, and it is apparent that 
as groups the patients are of comparable age and injury. 
There were 19 deaths in the first group; nine in the second and eleven in the 
third. The average ages of the patients who died were 34, 26 and 43 years, 
respectively. The average percent of full-thickness burn in the first group of deaths 
was 46 percent; in the second group, 40 percent; and in the third group, 52 per- 
cent. This illustrates that the patients in group 111 had more severe burns than 
the patients in groups I and 11, 
A review of the septicemia problem reveals that group I had 29 cases of 
septicemia out of a total of 41 patients. In group 11, there were 18 cases of 
septicemia out of 24 patients, and in the largest group, 61 patients in group 111, 
the incidence of septicemia dropped to its lowest point of 16. There were 17 
deaths in group I, nine in group I1 and six in group 111. There were 21 cases of 
pseudornonas septicemia in the first group; seven in the second; and three in the 
last. There were only two pseudomonas deaths in group 111 in contrast to 13 in  
group I. 
Results of this program have been encouraging to date and a continued 
program of evaluation is in progress. 
SUMMARY 
This progress report demonstrates a pseudomonas vaccine and hyperimmune 
plasma used in treating 61 patients with burns involving a minimum of 20 percent 
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of the body with full-thickness (third degree) loss of 40 percent total injury 
(partial thickness and full-thickness) . The incidence of septicemia had decreased 
and mortality due to pseudomonas septicemia, when it does occur, has been 
greatly reduced. 
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